Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel
Abstract
Abstract The European LeukemiaNet has periodically issued guidelines for the diagnosis and management of acute myeloid leukemia (AML) in adults. These consensus recommendations, most recently updated in 2022, incorporate recent advances in genomic testing, disease detection methods, target identification, and response assessment. Although similarities exist between AML in children and adults, pediatric AML is frequently characterized by unique cytogenetic and molecular features, which require distinct genetic and immunophenotypic diagnostics, therapeutic approaches, response assessment criteria, and supportive care strategies. To address these specific needs, an international panel of pediatric hematologist-oncologists, biologists, geneticists, and laboratory medicine scientists convened to develop recommendations for the diagnosis and management of AML in children, adolescents, and young adults (hereafter termed pediatric AML) that are discussed in this special report.
Article Details
Authors (25)
C. Michel Zwaan
1Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Sarah K. Tasian
Richard Aplenc
Lisa E. Brodersen
5Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, PA
Barbara Buldini
Barbara De Moerloose
Michael N. Dworzak
Linda Fogelstrand
Brenda E. S. Gibson
12Haematology Department, Royal Hospital for Children, University of Glasgow, Glasgow, United Kingdom
Bianca F. Goemans
1Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Henrik Hasle
13Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Betsy A. Hirsch
14Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN
Gertjan J. L. Kaspers
1Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Jan-Henning Klusmann
Matthew A. Kutny
17Division of Hematology/Oncology, Department of Pediatrics, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL
Thomas Lehrnbecher
16Division of Hematology/Oncology, Department of Pediatrics, Goethe University, Frankfurt, Germany
Franco Locatelli
IRCCS Ospedale Pediatrico Bambino Gesù Rome, Rome
Soheil Meshinchi
Arnaud Petit
20Department of Pediatric Hematology and Oncology, Armand-Trousseau Hospital Assistance Publique–Hôpitaux de Paris and Sorbonne University, Paris, France
Martina Pigazzi
Anne Tierens
21Laboratory Medicine Program, University Health Network and University of Toronto, Toronto, Canada
E. Anders Kolb
Dirk Reinhardt
23Gesellschaft für Pädiatrische Onkologie und Hämatologie, Essen, Germany
Daisuke Tomizawa
Todd M. Cooper
25Cancer and Blood Disorders Center, Seattle Children’s Hospital, Seattle, WA